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476Objective: The genes KRAS and EGFR have emerged as potential targets for therapy in lung adenocarcinoma;
mutations in these genes can be found in almost half of patients. In anticipation of the clinical importance of
molecularly defined adenocarcinoma subgroups for the treatment of patients with resected stages I through
III lung adenocarcinoma, the Memorial Sloan–Kettering Cancer Center (MSKCC) Departments of Surgery
and Pathology have collaborated since 2006 to conduct reflex testing of tumor specimens for EGFR and
KRAS mutations.
Methods: Using established methods, the identification of EGFR exon 19 deletions and exon 21 L858R muta-
tions was performed. In samples lacking these 2 sensitizing EGFR mutations, KRAS analysis was done.
Results:We studied a total of 1831 patients who had stage I through IV lung adenocarcinomas and detected 448
KRAS and 364 EGFR mutations. Of these patients, a subset of 855 (78%) patients with stages I through III
adenocarcinoma of the lung who underwent curative surgical resection at MSKCC were tested. In patients
with early stage disease, 158 EGFR mutations and 207 KRAS mutations were detected.
Conclusions: The results of the first 3 years of reflex testing at MSKCC reported here demonstrate the feasibil-
ity, clinical utility, and potential of this approach. This information allowed for enrollment of patients into
clinical trials to explore mutation-specific, directed therapy and led to retrospective studies related to patient out-
come. In addition, it may inform selection of chemotherapy for recurrent disease and may help to distinguish
multiple primary tumors from metastatic disease. (J Thorac Cardiovasc Surg 2011;141:476-80)Earn CME credits at
http://cme.ctsnetjournals.org
Despite successful surgery, half of patients with resected
non–small-cell lung cancer (NSCLC) recur and die within
5 years.1 In patients with resected stage II through III
NSCLC, 4 months of cisplatin-based chemotherapy im-
proves survival rates by nearly 20% (relative risk reduc-
tion), with an absolute risk reduction of 10% to 13%.2
Pathologic stage is the only prospectively validated clinical
factor used to select patients for adjuvant chemotherapy.3
More effective adjuvant therapies are sorely needed. The
most promising molecular markers for the selection of treat-
ment are somatic mutations in lung adenocarcinomas.emorial Sloan Kettering Cancer Center, New York, NY.
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The Journal of Thoracic and Cardiovascular SurgEpidermal growth factor receptor (EGFR) is a signaling
protein attached to the cell membrane. Ligand binding to
the extracellular portion of the EGFR protein leads to
increases in cellular proliferation, motility, adhesion, inva-
sion, blocking of apoptosis, and resistance to chemother-
apy.4 Erlotinib is an EGFR tyrosine kinase inhibitor
currently approved for patients with metastatic NSCLC.
Of all clinically relevant EGFR mutations, 90% are either
missense mutations in exon 21 or deletions in exon 19.5
Patients with deletions in exon 19 have better prognoses
than patients with missense mutations in exon 21 when
treated with erlotinib and gefinitib.6 EGFR mutations are
more common in people who have never smoked, in Asians,
and in women with adenocarcinoma.7 Patients with ad-
vanced NSCLC and EGFR exon 19 or 21 mutations have
been noted to have high rates of radiologic response to ge-
fitinib.8 A recent trial in East Asian nonsmokers or former
light smokers with stage IV adenocarcinoma evaluated
gefitinib against carboplatin and paclitaxel as first-line
chemotherapy. In the subgroup of patients with EGFR mu-
tations, patients treated with gefitinib had higher objective
responses—71% as opposed to 1%—and longer progres-
sion-free survival.9 These trials exemplify the importance
of EGFR mutations as predictors of response and clinical
benefit from tyrosine kinase inhibitors in patients with stage
IV lung adenocarcinoma.ery c February 2011
Abbreviations and Acronyms
ACCP ¼American College of Chest Physicians
NSCLC ¼ non–small-cell lung cancer
MSKCC ¼ Memorial Sloan–Kettering Cancer
Center
PCR ¼ polymerase chain reaction
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teins that regulate cell growth,differentiation, andapoptosis.10
KRAS mutations occur in 20% to 30% of lung adenocarci-
nomas.11 More than 80% occur in exon 2 of KRAS in codon
12, with the remaining mutations occurring in codons 13
and 61. Although detected in some who have never smoked,
they are found more often in current and former cigarette
smokers and have been associatedwith poor prognoses in sev-
eral studies.12,13 In stage IV patients,KRASmutations predict
lack of response toEGFR tyrosine kinase inhibitors and lower
efficacy of chemotherapy when combined with erlotinib.14
The results of a prospective clinical trial of adjuvant chemo-
therapy for resected stage IB-II NSCLC did not demonstrate
a benefit from adjuvant chemotherapy in the KRAS mutant
subgroup (HR, 0.95; 95%CI;P¼ .87).15AtMSKCC, routine
reflex testing forEGFR andKRASmutationswas instituted for
all patients with resected lung adenocarcinomas in 2006. Jus-
tification for this reflex testing is outlined inTable 1.Although
it does not guide standard practice, themolecular information
has been used to enroll patients in clinical trials of novel adju-
vant therapy specifically targeting EGFR and KRAS.3 Know-
ing that as much as 50% of patients with resected NSCLC
would experience recurrence, we believed that the results of
the molecular tests could inform the selection of chemother-
apy for recurrent disease. EGFR/KRAS testing has been
used to assist in distinguishing multiple primary tumors
from metastatic tumors.16
Resected specimens routinely provide excess tissue for
molecular profiling. In contrast, patients with advanced
NSCLC are usually diagnosed with a fine needle aspirate,
limiting available tissue for analysis. Universal testing of
all resected lung adenocarcinomas for EGFR and KRAS
mutations has allowed for unique research efforts, including
retrospective studies related to outcome and prospective
studies of novel agents. Herewe report the results of the first
3 years of reflex testing conducted by the pathology depart-
ment of our institution.MATERIALS AND METHODS
We tested all patients who underwent lung resection because of adeno-
carcinoma. EGFR/KRAS mutations are extremely uncommon in large cell
carcinomas, small cell carcinomas, and squamous cell carcinomas.17 At the
time of gross prosection, a slice of tumorwas frozen and retained alongwith
a corresponding section for paraffin embedding and hematoxylin and eosin
(H&E) staining. Initially, DNAwas extracted from frozen tissue. After ob-The Journal of Thoracic and Caserving that several cases lacked sufficient tumoral DNAwhen the frozen
tissues were used, we modified the process and instead extracted DNA
from formalin-fixed paraffin-embedded tissue to ensure that a sufficient
percentage of tumor cells (target>50%) was present in the tissue from
which the DNA was prepared. After microscopic examination confirmed
the diagnosis of adenocarcinoma, tissue was sent to our CLIA-certified
molecular diagnostic laboratory in the Department of Pathology for extrac-
tion of DNA and identification of EGFR exon 19 deletions and exon
21 L858R mutations by polymerase chain reaction (PCR) assay. Nonse-
quencing-based PCR assays are used to detect these mutations.18 In sam-
ples lacking these 2 sensitizing EGFR mutations, KRAS analysis is done
by direct sequencing of exon 2 using PCR products. Molecular profiling
for EGFR/KRAS has been approved by the New York State Department
of Health. Amolecular diagnostic report is created and forwarded to the pa-
tient’s medical record for inspection by the patient’s surgeon and medical
oncologist (Figure 1).RESULTS
Between 2006 and April 2009, tumors of 1831 patients
with stage I through IV adenocarcinoma of the lung under-
went reflex testing, and 448 KRAS and 364 EGFRmutations
were detected. Of those patients, 1097 with stages I through
III adenocarcinoma of the lung underwent curative surgical
resection at MSKCC. A subset of 855 patients (78%) were
tested. In the patients in the early stages, 158 EGFR muta-
tions and 207 KRAS mutations were detected (Table 2).
The group included 291 males and 564 females; 594 patients
were in stage I; 111were in stage II; and 147were in stage III.
In 2006, 124 patients underwent mutation testing; 19%
had EGFR mutations, and 23% had KRAS mutations
(Table 3). In 2007, 324 patients underwent mutation testing;
14% had EGFR mutations, and 20% had KRAS mutations.
In 2008, 293 patients underwent mutation testing; 25% had
EGFR mutations, and 30% had KRAS mutations. As of
April 2009, 114 patients have undergone mutation testing;
25% have EGFRmutations and 30% have KRASmutations
(Table 3). Already, 15% of these patients have experienced
recurrences, and genetic information from their resected
specimens has been used to select therapy.DISCUSSION
Reflex testing of adenocarcinomas for EGFR and KRAS
mutations at MSKCC over the past 3 years reveals some in-
teresting observations. Nearly 78% of patients with early-
stage disease have undergone mutation testing.
The majority of patients with resected adenocarcinoma
are females, at a nearly 2 to 1 ratio. It is unclear whether
this trend is the result of demographics unique to our patient
population, is related to the preponderance of adenocarci-
noma in females versus males, or is related to differing
smoking habits in females and males. This sex distribution
is not seen in our advanced-stage patients; in a database of
1081 cases of stage IV adenocarcinomas, 59% were
women. It is interesting that in a recent report concerning
a large group of patients that was screened for lung cancer,
it was found that the prevalence of screen-detected earlyrdiovascular Surgery c Volume 141, Number 2 477
TABLE 2. Patient characteristics
2006 2007 2008 2009
Male 34 112 108 37
Female 90 212 185 77
Stage I 76 234 203 81
Stage II 16 40 42 13
Stage III 29 50 48 20
Total tested 124 324 293 114
TABLE 1. Clinical utility of reflex testing in early-stage (I through III)
adenocarcinoma
 It informs selection of chemotherapy for recurrent disease.
 It may help to distinguish multiple primary tumors from metastatic
disease.
 It allows for enrollment of patients into clinical trials to explore mutation-
specific therapy.
 It encourages additional research efforts, including retrospective studies
related to patient outcome.
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women had less exposure to smoking.19
Most resections for NSCLC at MSKCC occur at stage I,
which is a stage of the disease for which no routine adjuvant
therapy exists.20 They are performed in a population of pa-
tients for whom opportunities to participate in clinical trial
are especially important. Counted together, EGFR and
KRAS mutation testing identifies a ‘‘driver mutation’’ in
nearly half of the cases of resected adenocarcinomas at
our institution.
To date, 15% of patients who have undergone reflex test-
ing of resected adenocarcinoma have experienced recur-
rence of disease. Given the short median follow-up, it is
no surprise that the majority of patients with early recur-
rence were found to have lymph-node metastases (ie, stage
II through III) at the time of surgery. In these patients, the
molecular characteristics of their tumors were immediately
available to inform the selection of therapy for recurrent,
stage IV disease. An alternative approach would be to test
for these mutations at the time of recurrence.FIGURE 1. Reflex testing flowchart
478 The Journal of Thoracic and Cardiovascular SurgPatients at MSKCC receive postoperative, cisplatin-
based chemotherapy according to established standards of
care.21 Pathologic stage is the most important factor in se-
lecting patients for adjuvant therapy. Previous data have
supported the role of adjuvant cisplatin-based chemother-
apy in patients with stage II through III NSCLC. The higher
the stage, the more benefit is derived from adjuvant chemo-
therapy.22 Other than stage, no clinical factors are predictive
of the benefits of treatment.
Historically, criteria developed by Martini and Melamed
and the American College of Chest Physicians (ACCP)
have been used to distinguish multiple primary lung tumors
from metastatic lesions.23,24 These criteria often provide
conflicting results. A recent report interpreted 7 patients’
tumors using the Martini-Melamed criteria, the ACCP
criteria, and comprehensive histologic subtyping. When
the Martini-Melamed criteria were applied, 6 of 7 patients
were determined to have had multiple primary lung
tumors. According to the ACCP criteria, 3 patients had
multiple primaries, and 3 had metastases; the seventh
patient’s case was indeterminate. However, based on
comprehensive histologic subtyping, all of the patients
had multiple primary lung tumors. Mutational testing also
suggested that the tumors were multiple primary lung
adenocarcinomas. This case series demonstrates that
molecular profiling can assist in clarifying clinical issues
and in resolving conflicts among existing clinical criteria.16
Reflex testing has allowed for retrospective studies of the
impact of gefitinib and erlotinib as adjuvant therapy for pa-
tients with stage I through III adenocarcinomas of the lung
that harbor an EGFRmutation. We have reported improved
disease-free survival rates in patients with completely re-
sected stage I through III adenocarcinomas with EGFRmu-
tations who were treated with perioperative gefitinib or
erlotinib compared to individuals who did not receive treat-
ment with EGFR TKI.25 We evaluated 150 patients (112
women, 38 men) who had completely resected stage I
through III lung adenocarcinoma and whose resection spec-
imens contained EGFR-activating mutations in exon 19 or
21. Of those patients, 42 (28%) received cytotoxic chemo-
therapy, and 48 (32%) received either erlotinib (n ¼ 26) or
gefitinib (n ¼ 22) postoperatively. The median time on
a TKI was 16 months. The median disease-free survival
(DFS) was 43 months in the patients who received TKI asery c February 2011
TABLE 3. Results
2006 2007 2008 2009 through April
Resected adenocarcinomas 334 328 312 123
Total tested 124 324 293 114
Percent tested 37 99 94 93
EGFR mutant 23 46 61 28
KRAS mutant 28 66 79 34
EGFR/KRAS wild type 73 212 153 52
Recurred 30 (24%) 61 (19%) 38 (13%) 3 (3%)
Stage I 13 (17%) 35 (15%) 19 (9%) 1 (1%)
Stage II 6 (38%) 11 (28%) 7 (17%) 1 (1%)
Stage III 11 (38%) 15 (30%) 12 (25%) 2 (20%)
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ling for stage, we found that individuals who received adju-
vant gefitinib or erlotinib had a better DFS (HR, 0.56; 95%
CI, 0.25–1.25; P¼ .157) than the non-TKI group. Currently
a multicenter phase-2 trial is evaluating the role of adjuvant
erlotinib in patients with resected adenocarcinomas. This
combined experience may serve as the basis for recom-
mending perioperative treatment with erlotinib, based
on the ‘‘reflex’’ identification of an EGFR mutation in all
patients following resection.
Reflex testing for EGFR and KRAS mutation at our insti-
tution has allowed for studies of the prognostic significance
of these molecular markers. We evaluated 1000 patients
(618 women) who had stage I (732), stage II (121), or stage
III (147) lung adenocarcinomas. Median follow-up was 16
months. After adjustment for stage, there was a trend toward
better survival rates in EGFR mutation-positive patients
(n ¼ 145) compared to wild type (n ¼ 588) (HR, 0.76;
95% CI, 0.45–1.30; P¼ .3). Therewas a trend toward worse
survival rates in patients withKRASmutation (n¼ 267) com-
pared to wild type (HR, 1.20; 95% CI, 0.83–1.70; P ¼ .4).
The 3-year survival proportions for each group were:
EGFR mutation 80% (95% CI, 0.67–0.89); KRAS mutation
73% (95% CI, 0.63–0.81); wild type 73% (95% CI,
0.69–0.78).26
Reflex testing has allowed us to select patients for
research studies of mutation-specific adjuvant therapy.
Currently, we have enrolled 23 patients in a trial of
GI-4000 (GlobeImmune, Inc., Louisville, Colo); recombi-
nant, heat-inactivated yeast (Saccharomyces cerevisiae)
engineered to express 1 of 3 mutated KRAS oncoproteins
(G12C, G12V, and G12D, representing 85% of the specific
KRAS mutations detected in outpatients).24,27 Patients with
KRAS mutations are immunized with a vaccine, and
immune response is recorded. As mentioned earlier,
patients with EGFR exon 19 or exon 21 mutations are
offered the opportunity to enroll in a phase II trial of
erlotinib as an adjuvant therapy. To date, 17 patients have
been enrolled in this trial.
Mutations in EGFR and KRAS are found in one third of
lung adenocarcinomas. We have demonstrated that theseThe Journal of Thoracic and Camolecular lesions can be readily identified in resected spec-
imens by reflex testing. As we have recently seen with the
identification of the EML4-ALK fusion gene,28 new genetic
lesions with therapeutic implications will emerge and can
be readily incorporated into the reflex testing process.
Our experience over the past 3 years has demonstrated
that reflex testing is feasible. The data obtained through
this mechanism provide patients and scientists opportuni-
ties for research, and they can also aid in clinical decision
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